Clinical Trial Update: Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years [Phase 3]

View source ↗

Summary

This Phase 3 trial compares conventional-dose lenalidomide, bortezomib, and dexamethasone (RVD) against high-dose therapy with autologous stem cell transplant i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Melphalan (Melphalan)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Myeloma | Phase 3 | Status: COMPLETED